← All trials
NCT02307396
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2014
- Primary completion
- May 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Technical University of MunichLead sponsor
- Technical University of MunichOverall official - principal investigator
Drugs studied
- flupentixol
- flupentixol
- bromperidol
- bromperidol
- fluphenazine
- fluphenazine
- fluspirilene
- fluspirilene
- ziprasidone
- ziprasidone
- haloperidol
- haloperidol
- olanzapine
- olanzapine
- perphenazine
- perphenazine
- pimozide
- pimozide
- risperidone
- risperidone
- sertindole
- sertindole
- thioridazine
- thioridazine
- paliperidone
- paliperidone
- amisulpride
- amisulpride
- zuclopenthixol
- zuclopenthixol
- quetiapine
- quetiapine
- Benperidol
- Benperidol
- sulpiride
- sulpiride
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.